Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,653 questions in 194 reviews · Gynaecology and Fertility
current versionsNo studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
GnRH analogues vs placebo or no treatment Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 1.58 [1.24, 2.01] | 605 participants | Very low |
GnRH analogues vs danazol Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 1.17 [0.9, 1.52] | 340 participants | Very low |
GnRH analogues vs progestogens Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 1.58 [0.96, 2.61] | 146 participants | Very low |
GnRH analogue vs GnRH antagonist Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 0.95 [0.79, 1.14] | 100 participants | Moderate |
GnRH analogue vs dilatation & curettage Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 20.12 [1.21, 333.63] | 92 participants | Very low |
Danazol vs no pretreatment Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 1.05 [0.8, 1.39] | 179 participants | Low |
Progestogens vs no pretreatment Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 0.54 [0.26, 1.12] | 50 participants | Low |
Danazol vs progestogens Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 1.89 [1.12, 3.18] | 103 participants | Low |
GnRHa or danazol vs no pretreatment Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding (2013) · Cochrane | RR 1.13 [0.89, 1.43] | 280 participants | Low |
Natural cycle IVF vs standard IVF Live birth per woman · Subfertile couples Natural cycle in vitro fertilisation (IVF) for subfertile couples (2013) · Cochrane | OR 0.68 [0.46, 1.01] | 2 studies · 425 participants | Moderate |
Natural cycle IVF vs standard IVF OHSS per woman · Subfertile couples Natural cycle in vitro fertilisation (IVF) for subfertile couples (2013) · Cochrane | OR 0.19 [0.01, 4.06] | 1 study · 60 participants | Very low |
Natural cycle IVF vs standard IVF Clinical pregnancy per woman · Subfertile couples Natural cycle in vitro fertilisation (IVF) for subfertile couples (2013) · Cochrane | OR 0.52 [0.17, 1.61] | 4 studies · 351 participants | Low |
Natural cycle IVF vs standard IVF Ongoing pregnancy per woman · Subfertile couples Natural cycle in vitro fertilisation (IVF) for subfertile couples (2013) · Cochrane | OR 0.72 [0.5, 1.05] | 3 studies · 485 participants | Moderate |
Natural cycle IVF vs standard IVF Multiple pregnancy per woman · Subfertile couples Natural cycle in vitro fertilisation (IVF) for subfertile couples (2013) · Cochrane | OR 0.76 [0.25, 2.31] | 2 studies · 527 participants | Very low |
Progestagen vs placebo AFS score · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | no estimate extracted | 1 study · 33 participants | Low |
Depot progestagen vs other treatment Side effects ‐ breakthrough bleeding/spotting · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 20.56 [6.44, 65.56] | 2 studies · 354 participants | Low |
Depot progestagen vs other treatment Side effects ‐ bloating · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 4.39 [1.71, 11.3] | 1 study · 80 participants | Very low |
Depot progestagen vs other treatment Side effects ‐ injection site reaction · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 20.64 [1.19, 358.23] | 1 study · 274 participants | Low |
Oral progestagens vs other treatment Patient assessed efficacy ‐ pain · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | no estimate extracted | 2 studies · 286 participants | Moderate |
Oral progestagens vs other treatment Objective efficacy at end of · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | no estimate extracted | 2 studies · 302 participants | Moderate |
Oral progestagens vs other treatment Side effects ‐ headache · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 0.58 [0.38, 0.87] | 3 studies · 613 participants | Moderate |
Oral progestagens vs other treatment Side effects ‐ hot flushes · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 0.49 [0.31, 0.76] | 3 studies · 613 participants | Low |
Oral progestagens vs other treatment Side effects ‐ genital bleeding · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 4.69 [2.47, 8.9] | 1 study · 271 participants | Low |
Oral progestagens vs other treatment Side effects ‐ amenorrhoea · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 4.95 [2.88, 8.52] | 1 study · 252 participants | Very low |
Oral progestagens vs other treatment Sleep disorder · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 0.19 [0.04, 0.9] | 1 study · 252 participants | Very low |
Progestagen vs placebo Patient assessed efficacy, sum of all symptoms · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | no estimate extracted | 1 study · 33 participants | Low |
Anti‐progestagen vs other treatment Patient assessed efficacy none or mild painful periods (dysmenorrhoea) · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 1.03 [0.55, 1.93] | 2 studies · 176 participants | Low |
Anti‐progestagen vs other treatment Objective assessment of efficacy at end of treatment (6 months) ‐ rAFS scores · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Anti‐progestagen vs other treatment Patient assessed efficacy painful periods visual analogue scale · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | no estimate extracted | 1 study · 55 participants | Moderate |
Anti‐progestagen vs other treatment Side effects ‐ seborrhoea · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 2.74 [1.69, 4.46] | 3 studies · 357 participants | Low |
Anti‐progestagen vs other treatment Side effects ‐ hirsutism · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 2.63 [1.6, 4.32] | 2 studies · 302 participants | Very low |
Anti‐progestagen vs other treatment Side effects ‐ hot flushes · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 0.65 [0.42, 0.99] | 3 studies · 357 participants | Very low |
Anti‐progestagen vs other treatment Side effects ‐ amenorrhoea · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 0.04 [0.01, 0.38] | 1 study · 49 participants | Low |
Progestagen vs placebo Patient assessed efficacy, sum of all symptoms · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | no estimate extracted | 1 study · 29 participants | Low |
Progestagen vs placebo Side effects ‐ acne · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 9.6 [1, 91.96] | 1 study · 33 participants | Very low |
Progestagen vs placebo Side effects ‐ oedema · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 35.2 [3.6, 344.19] | 1 study · 33 participants | Very low |
Depot progestagen vs other treatment Improvement in dysmenorrhoea · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 0.19 [0.05, 0.69] | 1 study · 274 participants | Low |
Depot progestagen vs other treatment Improvement in dysmenorrhoea · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 0.63 [0.37, 1.08] | 1 study · 274 participants | Low |
Depot progestagen vs other treatment Side effects ‐ hot flushes · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 0.3 [0.11, 0.83] | 2 studies · 354 participants | Low |
Depot progestagen vs other treatment Side effects ‐ amenorrhoea · patients with pain associated with endometriosis Progestagens and anti‐progestagens for pain associated with endometriosis (2012) · Cochrane | OR 21.18 [1.18, 380.9] | 1 study · 80 participants | Very low |
Intervention NR Prevalence of stress urinary incontinence within 2 years post surgery [ · Women requiring hysterectomy for benign conditions Total versus subtotal hysterectomy for benign gynaecological conditions (2012) · Cochrane | OR 1.45 [0.85, 2.47] | 955 participants | Moderate |
Intervention NR Prevalence of constipation within 2 years post surgery [ · Women requiring hysterectomy for benign conditions Total versus subtotal hysterectomy for benign gynaecological conditions (2012) · Cochrane | OR 0.8 [0.49, 1.31] | 555 participants | Low |
Intervention NR Satisfaction with sex within 2 years post surgery [ · Women requiring hysterectomy for benign conditions Total versus subtotal hysterectomy for benign gynaecological conditions (2012) · Cochrane | OR 1.04 [0.68, 1.59] | 454 participants | Low |
SERMS vs no treatment Percent change from baseline in leiomyoma size · patients with uterine leiomyomas Selective estrogen receptor modulators (SERMs) for uterine leiomyomas (2012) · Cochrane | no estimate extracted | 1 study · 23 participants | Very low |
SERMS (raloxifene 60mg) vs placebo Size (cm3) of leiomyoma · patients with uterine leiomyomas Selective estrogen receptor modulators (SERMs) for uterine leiomyomas (2012) · Cochrane | no estimate extracted | 1 study · 58 participants | Low |
SERMS (raloxifene 60mg) vs placebo Size (cm3) of leiomyoma · patients with uterine leiomyomas Selective estrogen receptor modulators (SERMs) for uterine leiomyomas (2012) · Cochrane | no estimate extracted | 1 study · 58 participants | Low |
SERMS (raloxifene 60mg) vs placebo Percent change from baseline in leiomyoma size in GHRH‐analogue treated women · patients with uterine leiomyomas Selective estrogen receptor modulators (SERMs) for uterine leiomyomas (2012) · Cochrane | no estimate extracted | 1 study · 91 participants | Low |
SERMS (raloxifene 180 mg) vs placebo Size (cm3) of leiomyoma · patients with uterine leiomyomas Selective estrogen receptor modulators (SERMs) for uterine leiomyomas (2012) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
SERMS (raloxifene 180 mg) vs placebo Size (cm3) of leiomyoma · patients with uterine leiomyomas Selective estrogen receptor modulators (SERMs) for uterine leiomyomas (2012) · Cochrane | no estimate extracted | 1 study · 59 participants | Low |
Black cohosh vs placebo Vasomotor symptoms: daily hot flush frequency · patients with menopausal symptoms Black cohosh (Cimicifuga spp.) for menopausal symptoms (2012) · Cochrane | no estimate extracted | 3 studies · 393 participants | Moderate |